A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolveTM MYOLIMUS ELUTING BIORESORBABLE CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

Trial Profile

A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolveTM MYOLIMUS ELUTING BIORESORBABLE CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Myolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions
  • Acronyms DESolve-I
  • Sponsors Elixir Medical Corporation
  • Most Recent Events

    • 16 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016 as per ClinicalTrials.gov record.
    • 19 Mar 2014 New source identified and integrated.ClinicalTrials.gov record
    • 16 May 2012 Lead Investigator (Verheye S) added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top